To validate either protein as a clinical biomarker, a larger prospective study would be required recording tumour and possible also serum immunohistochemistry (IHC) levels of S100A4 and OPN alongside clinical outcomes (Dancey et al, 2010). Here, SPP1 is linked to neoplasm.